Table 4 Patient and tumour characteristics in the 2nd line endocrine setting (n = 6)
From: Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
Variable -2nd line | n (%), median (range) |
|---|---|
Median age at AI initiation | 56 years (40–74) |
Performance status | |
0 | 2 (33%) |
1 | 4 (67%) |
Menopausal status | |
Premenopausal | 1 (17%) |
Postmenopausal | 5 (83%) |
Number of co-morbidities | |
0-1 | 5 (83%) |
2-3 | 1 (17%) |
Sites of metastases at time of AI initiation | |
Lung | 4 (67%) |
[Lung as only site of metastases] | 4 (67%) |
Peritoneum/pelvis | 2 (33%) |
Tumour volume at time of AI initiation | |
Low | 2 (33%) |
High | 4 (67%) |
Histological grade (Stanford) | |
Low | 5 (83%) |
High | 1 (17%) |
Hormone receptor status | |
ER | |
Moderate to strong (grade 2–3) | 5 (83%) |
Weak (grade 1) | 1 (17%) |
PgR | |
Moderate to strong (grade 2–3) | 4 (67%) |
Weak (grade 1)/ NA | 2 (33%) |
ER and PgR | |
Moderate to strong (grade 2–3) | 4 (67%) |
Weak (grade 1) | 1 (17%) |
% ER staining | |
>90% | 5 (83%) |
unknown | 1 (17%) |
% PgR staining | |
>90% | 2 (33%) |
>50% | 3 (50%) |
0% | 1 (17%) |
unknown | 2 (33%) |